Celldex Therapeutics reported $28.1M in Operating Expenses for its third fiscal quarter of 2022.

Trading Economics members can view, download and compare data from nearly 200 countries, including more than 20 million economic indicators, exchange rates, government bond yields, stock indexes and commodity prices.

The Trading Economics Application Programming Interface (API) provides direct access to our data. It allows API clients to download millions of rows of historical data, to query our real-time economic calendar, subscribe to updates and receive quotes for currencies, commodities, stocks and bonds.

Please Paste this Code in your Website
Operating Expenses Change
Abbvie ABBV:US USD 10.21B 1.08B
Agenus AGEN:US USD 64.42M 1.07M
Amgen AMGN:US USD 3.91B 504M
Applied Genetic Technologies AGTC:US USD 17.34M 705K
Aptinyx Inc APTX:US USD 14.66M 2.45M
Biocept BIOC:US USD 11.16M 4.54M
Bristol Myers Squibb BMY:US USD 8.75B 552M
Celldex Therapeutics CLDX:US USD 28.1M 8.46M
Cytrx CYTR:US USD 1.29M 7.73M
Glaxosmithkline GSK:US GBP 6.64B 790M
Immunogen IMGN:US USD 92.8M 17.59M
Nektar Therapeutics NKTR:US USD 77.93M 96.49M
Newlink Genetics NLNK:US USD 8.05M 280K
Northwest Biotherapeutics NWBO:US USD 16.28M 5.41M
Pfizer PFE:US USD 13.23B 2.41B
Rigel Pharmaceuticals RIGL:US USD 40.81M 1.97M
Roche Holding ROG:VX 20.75B 3.26B
Seattle Genetics SGEN:US USD 703.1M 72.49M